AI주식인사이트AI Stock Insight
D

삼천당제약

000250KOSDAQ의약품 제조업

39.4 / 100

Reference Date: 2026-06-10

Financial Score8.5 / 40
News Sentiment16.9 / 25
Momentum4.0 / 20
Disclosure10.0 / 15
AI Analysis: the high debt ratio poses financial risk, PER raises overvaluation concerns. Plunged 39.3% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Samcheon Pharmaceutical, established in 1943, is a leading manufacturer and distributor of prescription pharmaceuticals, specializing in antibiotics, cardiovascular treatments, digestive system medications, and ophthalmic solutions. In 2024, its consolidated sales reached 231.8 billion won, a 9.9% increase from the previous year, with its subsidiary Optus Pharmaceuticals reporting a 6.4% rise in sales to 87.16 billion won.

Number of Employees

436people

Average Salary

65.8M KRW

Score Calculation Basis

Detailed Financial Score

PER
1073.01Industry Average 11.930.0Point

89.9x industry avg (risky)

PBR
15.65Industry Average 0.890.0Point

17.6x industry avg (risky)

ROE
3.37Industry Average 4.012.5Point

Below industry avg

Debt Ratio
25.05Industry Average 12.430.0Point

2.0x industry avg (risky)

Trend 2023~20256.0 / 10 points
Revenue Growth Rate
2.0 / 3

Avg ▲9.7% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲74.1% (2-year basis)

ROE Trend
1.0 / 4

Avg ROE 0.1% (improving, 3yr)

Detailed News Sentiment

11 totalPositive 5Neutral 2Negative 4Average Sentiment Score 67.7

Detailed Momentum

52-week position1.0Point

Near 52w low (9%, downtrend)

Current 242,500Won52-week high 1,184,00052-week low 144,400
1-month return0.0Point

1m -39.30% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0
  • Neutral[기재정정]사업보고서 (2025.12)2026-06-04
  • Neutral투자판단관련주요경영사항(임상시험계획승인신청등결정) (제1형 당뇨병 환자를 대상으로 정상혈당 클램프 조건 및 식이 섭취 후, 경구용 인슐린 SCD0503과 피하 투여 인슐린 간의 상대적 생체이용률, 상대적 생물학적 효력 및 음식 영향 평가를 위한 임상시험)2026-05-29
  • Neutral분기보고서 (2026.03)2026-05-15